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Abstract
Surgical	resection	is	the	only	potentially	curative	treatment	for	patients	with	cholan‐
giocarcinoma.	For	both	perihilar	cholangiocarcinoma	(pCCA)	and	intrahepatic	chol‐
angiocarcinoma	 (iCCA),	5‐year	overall	 survival	of	about	30%	has	been	reported	 in	
large	 series.	 This	 review	 addresses	 several	 challenges	 in	 surgical	 management	 of	
cholangiocarcinoma.	The	first	challenge	is	diagnosis:	a	biopsy	is	typically	avoided	be‐
cause	of	the	risk	of	seeding	metastases	and	the	low	yield	of	a	brush	of	the	bile	duct.	
However,	about	15%	of	patients	with	suspected	pCCA	are	found	to	have	a	benign	
diagnosis	after	resection.	The	second	challenge	is	staging;	even	with	the	best	preop‐
erative	 imaging,	a	substantial	percentage	of	patients	has	occult	metastatic	disease	
detected	at	staging	laparoscopy	or	early	recurrence	after	resection.	The	third	chal‐
lenge	is	an	adequate	volume	and	function	of	the	future	liver	remnant,	which	may	re‐
quire	preoperative	biliary	drainage	and	portal	vein	embolization.	The	fourth	challenge	
is	a	complete	 resection:	a	positive	bile	duct	margin	 is	not	uncommon	because	 the	
microscopic	biliary	extent	of	disease	may	be	more	extensive	than	perceived	on	imag‐
ing.	The	fifth	challenge	is	the	high	post‐operative	mortality	that	has	decreased	in	very	
high	volume	Asian	centres,	but	remains	about	10%	in	many	Western	referral	centres.	
The	sixth	challenge	 is	 that	even	after	a	complete	 resection	most	patients	develop	
recurrent	disease.	Recent	randomized	controlled	trials	found	conflicting	results	re‐
garding	 the	benefit	of	adjuvant	chemotherapy.	The	 final	challenge	 is	 to	determine	
which	patients	with	cholangiocarcinoma	should	undergo	liver	transplantation	rather	
than	resection.
K E Y W O R D S
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1  | INTRODUC TION
Surgical	resection	is	the	only	potentially	curative	treatment	for	pa‐
tients	with	cholangiocarcinoma.	Cholangiocarcinoma	can	arise	any‐
where	 along	 the	 biliary	 tree.	 Intrahepatic	 (iCCA),	 perihilar	 (pCCA)	
and	distal	(dCCA)	cholangiocarcinoma	differ	in	tumour	characteris‐
tics	and	each	has	a	separate	American	Joint	Committee	on	Cancer	
(AJCC)	 staging	 system.1,2	 Consequently,	 they	 require	 a	 different	
treatment	approach.	dCCA	 is	beyond	the	scope	of	 this	 review	be‐
cause	diagnostic	work‐up	and	treatment	are	more	similar	to	cancer	
of	the	head	of	the	pancreas.
Most	patients	with	cholangiocarcinoma	are	 ineligible	 for	surgi‐
cal	 resection	because	of	metastatic	or	 locally	advanced	disease	at	
the	time	of	presentation.	Only	about	one	in	five	patients	with	pCCA	
is	eligible	for	surgery	at	the	time	of	presentation.3	Therefore,	even	
high‐volume	Western	centres	rarely	perform	more	than	two	resec‐
tion	per	month	 for	pCCA.4,5	The	main	 goal	 of	 surgery	 for	 cholan‐
giocarcinoma	 is	a	complete	 (R0)	 resection	with	 low	post‐operative	
mortality.	This	goal	requires	a	multidisciplinary	team	with	dedicated	
radiologists,	 interventional	 radiologists,	 endoscopists,	 anaesthesi‐
ologists,	 intensivists,	 hepatologists,	 pathologists	 and	 hepatobiliary	
surgeons	 with	 both	 surgical	 oncology	 and	 vascular	 or	 transplant	
skills.	Outcomes	are	best	in	high‐volume	centres.6
The	 aetiology,	 pathogenesis,	 risk	 factors	 and	 epidemiology	 of	
cholangiocarcinoma	 are	 reviewed	 in	 separate	 contributions	 in	 this	
issue.	The	aim	of	this	review	is	to	summarize	the	diagnostic	work‐up	
and	treatment	of	patients	with	resectable	pCCA	or	iCCA.
2  | PERIHIL AR CHOL ANGIOC ARCINOMA
2.1 | Diagnostic work‐up
In	this	review,	we	focus	on	the	diagnostic	work‐up	pertaining	to	sur‐
gical	treatment	options	(ie,	resection	and	liver	transplantation).	The	
diagnosis	pCCA	continues	to	pose	a	challenge.	The	early	symptoms	
are	non‐specific;	abdominal	discomfort	or	pain,	anorexia	and	weight	
loss.	Most	patients	present	with	a	high	serum	bilirubin.	Sometimes	
patients	complain	of	pruritus,	which	may	precede	jaundice	by	a	few	
weeks.	In	some	patients,	pCCA	is	incidentally	discovered	because	of	
abnormal	liver	function	tests.7
The	main	goal	of	the	diagnostic	work‐up	is	not	only	to	confirm	
the	presence	of	cancer,	but	also	to	assess	the	extent	of	bile	duct	
involvement,	vascular	involvement	(portal	vein	and	the	branches,	
hepatic	proper	artery	and	the	branches)	and	distant	metastases.8 
It	is	crucial	to	perform	all	imaging	before	biliary	drainage,	because	
ascertainment	of	the	biliary	and	vascular	extent	of	pCCA	is	more	
challenging	 after	 endoscopic	 stent	 placement.	 Moreover,	 the	
extent	of	 the	 tumour	determines	 the	 future	 liver	 remnant	 (FLR),	
which	determines	the	segments	to	be	drained	(see	also	section	on	
biliary	drainage).
Initial	 US	 examination	 shows	 intrahepatic	 biliary	 tree	 dila‐
tation,	 typically	 without	 dilatation	 of	 the	 gallbladder	 and	 the	
common	bile	duct.	CT	of	the	chest	and	abdomen	is	the	standard	
modality	for	staging	and	assessment	of	vascular	involvement.	MRI	
with	MRCP	and	diffusion‐weighted	 imaging	 can	be	of	 additional	
value	to	assess	the	biliary	extent	of	the	tumour.	Positron	emission	
tomography	(PET)	CT	should	not	be	routinely	used	in	the	diagnos‐
tic	work‐up	 because	 of	 low	 sensitivity	 and	 specificity.	However,	
in	 selected	patients	 (eg,	with	 increased	surgical	 risk	or	more	ad‐
vanced	disease),	PET	CT	may	be	justified	with	a	10%	yield	of	occult	
metastatic	 disease.9,10	 Studies	 comparing	 imaging	modalities	 are	
sparse.11
The	diagnosis	of	pCCA	requires	the	presence	of	a	malignant	ap‐
pearing	stricture	in	the	liver	hilum	and	at	least	one	of	the	following:
1.	Biopsy	or	cytology	positive	for	cancer	cells
2.	Polysomy	by	fluorescent	in	situ	hybridization	(FISH)
3.	Mass	forming	lession	on	CT	or	MRI	at	the	stricture
4.	CA	19.9	elevated	above	100	U/ml
Preoperative	 biopsies	 and	 intraluminal	 brushings	 have	 a	 high	
false‐negative	 rate.	 A	 negative	 brush	 or	 biopsy	 should	 not	 exclude	
the	diagnosis	of	pCCA	or	delay	proper	treatment.12	Endoscopic	ultra‐
sound‐guided	fine	needle	aspiration	or	biopsy	may	be	also	useful	for	
obtaining	a	diagnosis.	For	patients	eligible	for	surgery,	a	biopsy	is	not	
mandatory.	A	biopsy	should	be	restricted	to	selected	cases,	because	
of	the	risk	of	tumour	seeding	and	tract	recurrences.	The	indication	for	
biopsy	should	always	be	discussed	at	a	hepatobiliary	multidisciplinary	
team	meeting	that	should	include	a	transplant	surgeon.	A	preoperative	
biopsy	is	contraindicated	if	a	patient	is	eligible	for	liver	transplantation.
MRCP	has	 replaced	 endoscopic	 retrograde	 cholangio‐pancrea‐
tography	(ERCP)	to	determine	the	biliary	extent	of	the	tumour.	ERCP	
with	endoluminal	biopsy	may	play	a	role	in	selected	patients	when	
pathological	 confirmation	 is	 justifed.	 The	 differential	 diagnosis	 of	
pCCA	includes:	choledocholithiasis,	benign	focal	stenosis	of	the	he‐
patic	ducts,	Mirizzi	syndrome,	gallbladder	cancer,	primary	sclerosing	
cholangitis	(PSC),	autoimmune	cholangitis	and	metastatic	disease	to	
Key points
•	 Pathological	confirmation	before	surgery	is	not	manda‐
tory	in	patients	with	cholangiocarcinoma.
•	 All	imaging	for	cholangiocarcinoma	must	be	performed	
before	biliary	drainage.	After	drainage	it	is	harder	to	de‐
termine	resectability.
•	 Preoperative	 biliary	 drainage	may	 do	more	 harm	 than	
good	in	patients	with	an	FLR	above	50%.	A	hepatobiliary	
surgeon	 experienced	 with	 cholangiocarcinoma	 should	
be	consulted	prior	to	biliary	drainage.
•	 Portal	 vein	 embolization	 (PVE)	 is	 recommended	 in	 pa‐
tients	with	an	FLR	of	less	than	40%.
•	 Multiple	 tumors	 and	 positive	 lymph	 nodes	 are	 poor	
prognostic	factors	for	iCCA,	but	do	not	preclude	5‐year	
survival	after	resection.
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the	bile	duct	or	hepatoduodenal	lymph	nodes	(eg,	colorectal	cancer).	
In	about	15%	of	patients	who	underwent	a	resection	for	apparent	
pCCA,	final	pathological	examination	found	benign	disease.13
2.2 | Indication to resection
Given	 that	 surgery	 provides	 the	 only	 chance	 for	 cure	 of	 pCCA,	
hepatobiliary	resection	is	indicated	when	it	is	both	anatomically	and	
physiologically	feasible.	The	goal	for	surgery	is	to	achieve	an	R0	re‐
section	while	preserving	adequate	vascular	 inflow	to	and	function	
of	the	FLR.	This	can	be	very	difficult,	given	the	localization	of	these	
tumours	in	the	hepatic	hilum	in	intimate	relation	with	the	portal	vein	
and	hepatic	artery.
pCCA	 is	 typically	 stratified	 according	 to	 the	 Bismuth‐Corlette	
based	on	the	biliary	extent	of	the	tumour14	and	the	AJCC	classifica‐
tion	systems1	that	considers	local	 (biliary	and	vascular)	and	distant	
tumour	extent.	The	Blumgart	system	also	considers	hepatic	lobar	at‐
rophy.15	Regardless	of	the	staging	system,	it	is	difficult	to	accurately	
evaluate	resectability	preoperatively,	and	the	definitive	decision	to	
resect	or	not	is	made	at	surgical	exploration.	For	example,	the	biliary	
extent	of	the	tumour	towards	the	segmental	bile	ducts	is	often	more	
extensive	at	final	pathology,	than	judged	on	preoperative	imaging.
In	the	majority	of	patients,	radical	surgical	resection	of	pCCA	re‐
quires	an	(extended)	hemi‐hepatectomy,	and	not	only	the	patient's	
functional	 status	 (ie,	 co‐morbid	 conditions,	nutrition,	performance	
status)	but	 also	 the	volume	and	 function	FLR	needs	 to	be	consid‐
ered.	Traditionally,	a	“safe”	liver	resection	has	been	considered	one	
leaving	an	FLR	of	at	least	25%	of	the	preoperative	liver	volume	in	pa‐
tients	with	normal	liver	parenchyma	or	at	least	30%	to	40%	in	livers	
that	are	compromised	by	steatosis,	chronic	cholestasis,	cirrhosis	or	
chemotherapy.16,17	FLR	function	can	be	assessed	more	formally	by	
examining	hepatocellular	uptake	and	excretion	 (indocyanine	green	
clearance),	 uptake	 and	 biotransformation	 (13C‐methacetin	 breath	
test,	LiMAx),	and	uptake	(hepatobiliary	scintigraphy).	These	function	
tests	 can	 be	 combined	with	 SPECT‐CT	 to	 differentiate	 functional	
from	 non‐functional	 liver	 tissue.18	 When	 the	 FLR	 is	 insufficient,	
strategies	 to	 increase	 the	 FLR	 should	 be	 considered	 (see	 sections	
below	on	portal	vein	embolization).
2.3 | Preoperative biliary drainage
Obstructive	 cholangitis	 is	 an	 absolute	 indication	 for	 preoperative	
biliary	drainage	(PBD).	In	the	absence	of	cholangitis,	PBD	of	the	FLR	
is	debated,	because	it	may	cause	cholangitis	that	is	associated	with	
post‐operative	 liver	 failure	 and	 mortality.	 The	 indication	 for	 PBD	
must	therefore	be	cautiously	evaluated	by	a	hepatobiliary	multidis‐
ciplinary	team.
Obstructive	 jaundice	 is	 associated	 with	 a	 pro‐inflammatory	
state.19	Some	series	reported	an	association	between	serum	biliru‐
bin	and	post‐operative	complications,20,21	and	the	authors	therefore	
advocated	 routine	 PBD.	 However,	 a	 randomized	 controlled	 trial	
(RCT)	 for	 patients	 with	 periampullary	 tumours	 found	 an	 increase	
in	perioperative	complications	after	PBD.22	Consequently,	patients	
with	resectable	dCCA	and	a	bilirubin	 level	below	15	mL/dL	should	
undergo	 a	 pancreatoduodenectomy	 without	 preoperative	 biliary	
drainage.	Because	 liver	resection	 in	 jaundiced	patients	was	 judged	
at	higher	 surgical	 risk,	most	 surgeons	 continued	PBD	 in	 jaundiced	
patients	 with	 pCCA.6	 Several	 retrospective	 studies	 reported	 that	
PBD	 is	associated	with	 infectious	complications,	and	cholangitis	 is	
an	independent	prognostic	factor	for	post‐operative	mortality.23,24 
Another	 drawback	 of	 PBD	 is	 the	 risk	 of	 clinical	 deterioration	 or	
progressive	disease	because	of	complications	secondary	to	PBD	in	
about	15%	of	pCCA	patients.25
In	pCCA	patients	with	an	insufficient	FLR	(ie,	below	40%),	PBD	of	
the	FLR	is	required	prior	to	portal	vein	embolization	(PVE),	because	
biliary	obstruction	impairs	liver	regeneration.	For	patients	with	a	FLR	
volume	above	50%	(eg,	requiring	a	left	hemihepatectomy),	the	risk	of	
cholangitis	and	related	mortality	after	drainage	does	not	justify	the	
potential	benefit	of	biliary	decompression.4,24
Two	procedures	 to	 drain	 the	 bile	 ducts	 are	 available:	 percuta‐
neous	 transhepatic	 biliary	 drainage	 (PTBD)	 and	 endoscopic	 biliary	
drainage	 (EBD).	 Two	 recent	meta‐analyses,	 found	 a	 higher	 proce‐
dure	conversion,	cholangitis	and	pancreatitis	rate	in	the	EBD	group	
without	 showing	 differences	 in	 post‐operative	 complications	 and	
survival.25,26	A	recent	RCT	comparing	PTBD	to	EBD	was	stopped	for	
excess	mortality	 in	the	PTBD	group	(41%	vs	11%),	whereas	severe	
preoperative	drainage‐related	complications	were	comparable	in	the	
two	populations.	However,	the	sample	size	of	this	study	was	small	
(27	patients	per	arm).27
To	 overcome	 the	 morbidity	 of	 EBD,	 endoscopic	 nasobiliary	
drainage	(ENBD)	has	been	proposed	in	Japan.	They	report	a	lower	
rate	 of	 conversion	 to	 PTBD.28	Others	 failed	 to	 show	differences	
when	comparing	ENBD	with	EBD	and	PTBD.29	Among	the	draw‐
backs	 of	 ENBD	 are	 the	 patient	 discomfort	 and	 the	 possibility	 of	
accidental	dislodgment.	Because	cholangitis	 is	the	main	source	of	
morbidity	of	PBD,	the	placement	of	a	PTBD	above	the	ampulla	has	
been	advocated	to	reduce	bacterial	contamination.30	Dislocation	of	
the	tip	of	the	PTBD	proximal	to	the	tumour	is	a	challenging	compli‐
cation	of	this	strategy.
Based	 on	 the	 current	 evidence,	 a	 reasonable	 approach	 would	
be	to	perform	drainage	of	the	FLR	only	in	patients	presenting	with	
cholangitis	as	well	as	in	patients	with	both	a	bilirubin	level	exceeding	
4	mL/dL	and	an	FLR	below	40%.	Drainage	of	the	contralateral	liver	is	
reserved	for	those	patients	with	persistent	jaundice	and/or	sepsis.	In	
the	absence	of	large	RCTs,	there	is	no	definitive	evidence	to	recom‐
mend	PTBD,	EBD	or	ENBD.
2.4 | Portal vein embolization and ALPPS
An	inadequate	FLR	volume	and	function	poses	the	patient	at	risk	
to	post‐hepatectomy	liver	failure	(PHLF).	PVE	aims	to	decrease	the	
risk	of	PHLF	by	occluding	 the	portal	 vein	 to	 the	 side	of	 the	 liver	
that	 is	 resected,	causing	hypertrophy	of	 the	FLR.31,32	 In	 two	sys‐
tematic	 reviews,	preoperative	PVE	was	associated	with	a	relative	
increase	in	FLR	of	about	40%	and	a	2.5%	adverse	events	rate.31,32 
A	more	 recent	 review	details	 the	 four	 largest	 studies	on	PVE	 for	
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pCCA,	conducted	in	a	total	of	586	patients.33‐37	Only	one	patient	
died	because	of	PHLF.
No	consensus	on	 the	optimal	FLR	cut‐off	 to	perform	PVE	ex‐
ists.33	 In	most	 studies,	 cutoffs	 of	 the	 FLR	 range	 from	 20%‐40%,	
sometimes	 in	 combination	with	 assessment	of	 indocyanine	 green	
clearance.33	A	study	in	217	Dutch	and	US	patients	detailed	a	model	
to	predict	PHLF,	consisting	of	FLR	volume,	jaundice,	cholangitis	and	
preoperative	serum	bilirubin.	The	model	had	a	good	predictive	ac‐
curacy	with	a	c‐index	of	0.79.38	One	of	the	most	experienced	cen‐
tres	 in	 the	world	 recommends	PVE	 for	 an	 FLR	 below	40%.6	 This	
approach	resulted	in	a	PHLF	(grade	B/C)	rate	of	3.2%	and	a	post‐op‐
erative	mortality	rate	of	1.4%.	Several	studies	investigated	the	pre‐
dictive	value	of	liver	function	tests.	99mTc‐mebrofenin	scintigraphy	
was	evaluated	in	a	cohort	of	216	pCCA	patients.	The	authors	con‐
cluded	 that	 scintigraphy	helped	predicting	PHLF.39	 The	 challenge	
of	liver	function	tests	is	that	studies	have	not	shown	how	they	can	
avoid	unnecessary	PVE	in	patients	with	a	small	FLR	volume	or	avoid	
PHLF	by	recommending	PVE	in	patients	with	a	large	FLR	volume.
Associating	 liver	 partition	 and	 portal	 vein	 ligation	 for	 staged	
hepatectomy	 (ALPPS)	 is	 another	 option	 for	 patients	 with	 a	 small	
FLR.	During	the	first	procedure	of	ALPPS,	 the	 liver	parenchyma	 is	
(partially)	 transected	with	portal	vein	 ligation	of	 the	 liver	with	 the	
tumour.	 The	 second	 stage,	 after	 the	 FLR	 has	 become	 hypertro‐
phic,	 involves	the	resection.40,41	 In	a	recent	study,	conducted	with	
data	 from	the	 international	ALPPS	registry,	mortality	was	44%	for	
ALPPS	patients,	vs	24%	for	matched	non‐ALPPS	patients	who	had	a	
similar	FLR.	The	authors	concluded	that	PVE	remains	the	standard	
approach.42	Meanwhile,	 techniques	 for	ALPPS	have	become	more	
refined,	but	ALPPS	should	not	be	 the	 initial	 approach	 for	patients	
with	pCCA.
2.5 | Approach to resection
The	majority	of	patients	with	pCCA	require	an	(extended)	hemi‐hepa‐
tectomy	with	resection	of	the	extrahepatic	bile	duct	(Figure	1).	Right	
trisectionectomy	has	 the	advantage	of	a	greater	 length	of	 the	 left	
hepatic	duct	(2‐3	cm)	as	opposed	to	the	right	duct	(<1	cm).43	En‐bloc	
resection	of	the	caudate	lobe	is	recommended	because	the	tumour	
typically	extends	into	the	caudate	lobe	via	small	branches	draining	
into	 the	 right	or	 left	hepatic	ducts	or	 the	biliary	confluence.44	For	
Bismuth	 IIIB	 tumours,	 a	 left	 hepatectomy	 or	 trisectionectomy	 ex‐
tended	to	second‐order	biliary	radicals	is	needed,	often	requiring	re‐
construction	of	multiple	right‐sided	ducts.45	dCCA	(ie,	located	in	the	
intrapancreatic	bile	duct),	is	treated	with	a	pancreatoduodenectomy.	
Resection	of	only	the	extrahepatic	bile	duct	may	be	considered	for	
Bismuth	I	pCCA,	especially	in	frail	patients.	However,	in	a	study	of	
patients	with	Bismuth	I	or	II	tumours,	5‐year	survival	was	30%	with	
extrahepatic	bile	duct	resection	alone	vs	50%	with	en‐bloc	liver	re‐
section.46	 Lymphadenectomy	 of	 locoregional	 lymph	 nodes	 in	 the	
hepatoduodenal	ligament	is	recommended,	but	has	a	bigger	impact	
on	staging	than	on	improving	survival.
F I G U R E  1   (A)	Resected	specimen:	extended	right	
hemihepatectomy	including	segment	I,	extrahepatic	bile	duct,	
portal	vein	bifurcation	and	hilar	tissue.	Long	suture	at	proximal	
cut	end	of	left	bile	duct	and	forceps	in	resected	portal	vein	
bifurcation.	(B)	Lateral	view	of	liver	remnant	(segments	II,	III	and	
part	of	IV)	after	extended	right	hemihepatectomy	with	end‐to‐end	
anastomosis	of	the	portal	vein	and	transected	left	bile	duct	visible	
below	left	portal	vein,	prior	to	hepaticojejunostomy.	(C)	Anterior	
view	of	liver	remnant	(segments	II,	III	and	part	of	IV)	after	extended	
right	hemihepatectomy
(A)
(B)
(C)
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Portal	vein	resection	and	reconstruction	may	be	required	and	may	
improve	resection	rates,	R0	resection	rates	and	survival.6,47	Hepatic	
artery	resection	and	reconstruction	has	also	been	reported,	though	
morbidity	and	mortality	rates	can	be	high	and	survival	with	main	or	uni‐
lateral	hepatic	artery	involvement	is	poor.48,49	A	staging	laparoscopy	
to	rule	out	undetected	liver	or	peritoneal	metastases	is	recommended	
with	a	yield	above	20%	in	many	studies.50	Results	of	minimal‐invasive	
resection	for	pCCA	have	been	mostly	disappointing.51
2.6 | Perioperative systemic chemotherapy
Beside	the	role	of	chemoradiotherapy	(CRT)	in	liver	transplantation	
(discussed	below),	the	benefit	of	preoperative	therapy	has	not	been	
established.	Nelson	et	al	reported	R0	resection	of	91%	in	twelve	
patients	treated	preoperatively	either	for	borderline	resectable	or	
unresectable	extrahepatic	cholangiocarcinoma;	these	patients	also	
showed	a	better	5‐year	survival	rate	compared	to	the	33	patients	
who	did	not	receive	neoadjuvant	treatment	(53%	vs	23%).52	More	
recently,	a	 retrospective	study	by	a	South	Korean	group	focused	
on	 patients	 with	 locally	 advanced	 pCCA.53	 The	 twelve	 patients	
who	received	preoperative	CRT,	compared	to	the	45	who	did	not,	
showed	 a	 higher	 rate	 of	 R0	 resections	 that	was	 not	 statistically	
different	(83%	vs	64%,	P	=	0.32)	and	no	difference	in	disease‐free	
survival	 (DFS)	 and	 overall	 survival	 (OS).	 The	 phase	 II	 trial	 of	 the	
NACRAC	study	is	currently	in	progress:	twenty‐four	patients	with	
cholangiocarcinoma	 have	 been	 recruited	 and	 R0	 resection	 has	
been	 obtained	 in	 71%.54	 With	 all	 the	 limitations	 of	 the	 studies	
above,	such	as	small	samples	and	different	therapeutic	regimens,	
preoperative	 CRT	 has	 proved	 to	 be	 safe	 and	 seems	 to	 enhance	
R0	 resection	 rate	 for	 (borderline)	 unresectable	 pCCA.	Definitive	
data	 from	the	NACRAC	study	are	awaited	to	determine	whether	
neoadjuvant	 CRT	 also	 improves	 survival	 (UMIN000000992	 and	
UMIN000001754).
With	regards	to	the	role	of	adjuvant	treatment	for	pCCA,	more	
studies	are	available.	Firstly,	a	large	Japanese	RCT,	including	118	pa‐
tients	with	cholangiocarcinoma,	had	failed	to	demonstrate	a	better	
OS	for	patients	(n	=	58)	treated	with	mitomycin	and	5‐FU	after	sur‐
gery,	compared	to	the	controls	 (n	=	60)	who	had	not	 received	any	
adjuvant	 treatment.55	 Later	 studies	 found	 an	 improvement	 in	OS	
after	adjuvant	treatment,	especially	for	patients	with	positive	lymph	
nodes.56,57	In	particular,	in	a	cohort	of	260	patients	who	underwent	
R0/R1	resection	for	pCCA,	Kang	reported	a	statistically	significant	
survival	benefit	with	5‐FU‐based	adjuvant	regimen	for	patients	with	
positive	lymph	nodes.58	This	result	has	recently	been	confirmed	on	
multivariate	analysis	by	a	multicentre	retrospective	study	of	249	pa‐
tients	after	curative	resection	for	pCCA.59	Most	adjuvant	RCTs	in‐
clude	all	patients	with	biliary	tumours.	These	RCT	show	conflicting	
results	as	discussed	below	in	the	section	on	iCCA.
2.7 | Outcomes after resection
Outcomes	 for	 patients	 with	 resectable	 pCCA	 depend	 on	 three	
factors:
1.	Tumour	characteristics:	 local	extent	of	 the	tumour,	 tumour	dif‐
ferentiation,	 lymphovascular,	 perineural	 and/or	 microvascular	
invasion,	 lymph	node	 involvement	 and	 the	 presence	of	 distant	
metastasis.
2.	Whether	or	not	a	patient	is	considered	for	resection	at	a	multidis‐
ciplinary	meeting	including	experienced	hepatobiliary	surgeons.
3.	The	 surgical	 approach	 aiming	 at	 a	 radical	 (R0)	 resection,	 and	
perioperative	morbidity	and	mortality.
The	reported	3‐	and	5‐year	survival	rates	after	resection	for	pCCA	
are	around	45%	(35	to	60%)	and	30%	(15	to	40%).6,36,60,61	Most	pa‐
tients	are	not	cured	after	resection	for	pCCA;	about	80%	will	develop	
recurrent	 disease	mostly	within	 two	 years	 after	 surgery.62,63	 R0‐re‐
section	 rates	 range	 from	50%	 to	90%.	About	35%	of	 patients	 have	
positive	lymph	nodes	(pN1).	These	two	parameters	are	the	main	fea‐
tures	determining	survival.	While	an	R0‐resection	 is	associated	with	
a	5‐year	survival	of	up	to	60%,	it	is	less	than	10%	for	R1‐resections.	In	
case	of	negative	lymph	nodes,	5‐year	survival	is	reported	up	to	55%	
vs	 less	than	20%	in	case	of	positive	 lymph	nodes	–	regardless	of	an	
R0‐resection.
Another	 important	 tumour	 characteristic	 is	 tumour	 differen‐
tiation	(well	vs	moderate/poor),	although	not	as	strong	as	R‐status	
and	nodal	involvement.	Other	poor	prognostic	factors	are	lympho‐
vascular	 invasion,	 microvascular	 invasion	 and	 perineural	 invasion.	
Their	 impact,	however,	mostly	disappears	 in	multivariable	analysis,	
adjusting	for	R	status,	nodal	involvement	and	tumour	differentiation.	
Several	nomograms	predicting	prognosis	have	been	devised.64,65
The	early	post‐operative	(procedure‐related)	mortality	is	around	
10%	in	large	Western	centres,	but	may	vary	considerably	from	2%	to	
15%.4,5,24	Italian	and	French	multicentre	studies	both	found	a	post‐
operative	mortality	of	about	10%.	Nagino	reports	a	mortality	of	11%	
before	1990	and	1.4%	after	2005.6	Common	serious	complications	
are	PHLF,	biliary	complications,	infectious	complications	and	vascu‐
lar	complications.
In	an	attempt	to	improve	the	R0	resection	rate,	more	extensive	
resections	 have	 been	 proposed.	 One	 type	 of	 extended	 resection	
for	 pCCA	 is	 combining	 liver	 resection	with	 a	 pancreatoduodenec‐
tomy,	particularly	in	patients	in	whom	the	tumour	extends	towards	
the	distal	bile	duct.	Post‐operative	mortality	and	long‐term	survival	
are	favourable	in	high‐volume	centres,	but	poor	in	less	experienced	
centres.
Many	publications	have	shown	that	both	the	R0‐resection	rates	
and	post‐operative	mortality	 rates	depend	strongly	on	 the	experi‐
ence	of	 the	centre.66,67	These	 results	clearly	argue	 for	performing	
surgery	 in	patients	with	pCCA	only	 in	highly	experienced	centres.	
However,	about	25%	of	patients	will	have	an	R1	resection,	even	in	
experienced	centres.	Only	a	liver	transplantation	(LT)	could	reassure	
an	R0	resection	in	these	patients.
2.8 | Liver transplantation
The	 rationale	 of	 LT	 in	 patients	 with	 pCCA	 is	 to	 avoid	 two	 unfa‐
vourable	outcomes	of	 surgical	 resection;	 a	positive	margin	and	an	
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inadequate	FLR	with	PHLF.	Furthermore,	LT	 is	effective	 in	 remov‐
ing	 the	 underlying	 liver	 disease,	 such	 as	 PSC.68	 Early	 experience	
with	 LT	 for	 pCCA	was	poor.	 The	207	LT	patients	 reported	by	 the	
Cincinnati	Transplant	Tumour	Register	(from	1968	to	1997)	had	a	5‐
year	survival	of	23%.69	In	Spain,	France	and	Germany,	a	similar	series	
reported	a	3‐year	survival	rate	of	30%‐38%	with	very	high	rate	of	
recurrent	disease.70,71
The	Mayo	Clinic	protocol	(Table	1)	for	patients	with	unresectable	
pCCA,	 introduced	 in	 the	 1993	 (based	 on	 a	 previous	University	 of	
Nebraska	study),	 represented	a	breakthrough.72	The	protocol	con‐
sists	of	external	beam	radiation	(40‐45	Gy)	followed	by	transcathe‐
ter	radiation	(20‐30	Gy)	with	iridium	wires,	intravenous	5‐flurouracil	
administered	 for	 chemosensitization	 during	 radiation	 therapy,	 and	
capecitabine	 administered	 afterward	while	waiting	 LT.73,74	 Staging	
surgery	with	lymph	node	biopsies	is	performed	after	brachytherapy.	
The	 reported	 intention‐to‐treat	 survival	 rates	 at	 1,	 3	 and	 5	years	
were	82%,	62%	and	56%	respectively.	The	overall	survival	after	LT	
at	1,	3	and	5	years	was	91%,	81%	and	74%	respectively.75	These	fa‐
vourable	data	were	subsequently	reproduced	in	a	multicentre	study	
including	12	high‐volume	centres	in	the	US.76	The	5‐years	intention‐
to‐treat	survival	was	similar	(53%).	Notably,	more	than	two‐thirds	of	
the	patients	had	PSC	as	underlying	disease,	compared	to	about	5%	
in	other	pCCA	cohorts.
Whether	the	results	of	the	Mayo	Clinic	series	are	because	of	
careful	selection	of	the	patients	enrolled	or	to	the	efficacy	of	the	
pretransplant	 therapy	 is	 still	 debated.	 In	 a	 retrospective	 study,	
Mantel	identified	28	patients	with	pCCA	who	met	the	strict	selec‐
tion	criteria	 for	the	Mayo	Clinic	protocol	but	had	not	undergone	
neo‐adjuvant	chemoradiation	therapy.77	Five‐year	survival	in	this	
subgroup	was	59%,	which	is	comparable	to	the	results	obtained	in	
the	Mayo	series.
A	further	criticism	to	the	results	of	Mayo	protocol	is	that	in	the	
case	of	 a	 patient	with	 a	 negative	 cytology,	 negative	FISH,	 and	no	
residual	 tumour	 in	 the	 specimen	 after	 transplant	 the	 question	 re‐
mains	whether	the	patient	ever	had	a	cancer.	The	authors	estimate	
this	possibility	to	be	about	15%	of	patients.78	However,	the	high	risk	
of	 recurrence	 after	 transperitoneal	 biopsy	 justifies	 this	 approach	
at	 least	 until	 new	 and	 more	 accurate	 diagnostic	 techniques	 are	
developed.
Ethun	et	al	reported	that	patients	resected	for	pCCA	and	meet‐
ing	transplantation	criteria	had	a	significantly	worse	5‐year	survival	
compared	to	patients	who	received	LT	(18%	vs	64%).68	Among	pa‐
tients	who	underwent	resection	for	tumours	smaller	than	3	cm	with	
node‐negative	disease,	and	after	excluding	PSC	patients,	transplant	
was	still	associated	with	improved	OS	(5‐year:	54%	vs	29%;	P = 0.03).
Prioritization	to	LT	for	pCCA	patients	is	one	of	the	most	debated	
issues.	 In	2009,	the	UNOS	Board	of	Directors	voted	to	 implement	
the	allocation	changes	adopting	the	Mayo	Clinic	criteria	for	a	MELD	
score	exception	adjustment.	How	the	introduction	of	“Share	35”	pol‐
icy	will	affect	the	results	of	LT	in	pCCA	is	not	known	yet.	In	Italy,	a	
TA B L E  1  Mayo	clinic	protocol
Mayo	clinic	protocol External	beam	radiation	therapy	(45	Gy	in	30	fractions,	1.5	Gy	twice	
daily)
Brachytherapy	(20	Gy	at	1	cm	in	approximately	20‐25	h)	–	adminis‐
tered	2	wks	following	completion	of	external	beam	radiation	therapy
Capecitabine	–	administered	until	the	time	of	transplantation,	held	
during	perioperative	period	for	staging
Abdominal	exploration	for	staging	–	as	time	nears	for	deceased	donor	
transplantation	or	day	prior	to	living	donor	transplantation
Liver	transplantation
Inclusion	criteria Diagnosis	of	pCCA	(transcatheter	biopsy	or	brush	cytology,	CA	
19‐9	>	100	mg/mL	and/or	a	mass	on	cross‐sectional	imaging	with	a	
malignant	appearing	stricture	on	cholangiography)
Unresectable	tumour	above	cystic	duct	(pancreatoduodenectomy	for	
microscopic	involvement	of	CBD,	resectable	pCCA	arising	in	PSC)
Radial	tumour	diameter	3	cm
Absence	of	intrahepatic	and	extrahepatic	metastases
Candidate	for	liver	transplantation
Exclusion	criteria Intrahepatic	cholangiocarcinoma
Uncontrolled	infection
Prior	radiation	or	chemotherapy
Prior	biliary	resection	or	attempt	resection
Intrahepatic	metastases
Evidence	of	extrahepatic	disease
History	of	other	malignancy	within	5	years
Transperitoneal	biopsy	(including	percutaneous	and	EUS‐guided	FNA)
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new	allocation	policy	was	proposed	allowing	the	use	of	5%	of	donors	
for	 patients	 with	 non‐hepatocellular	 carcinoma	 (HCC)	 oncological	
indications	including	pCCA.79
2.9 | Locoregional treatments
When	a	patient	is	not	eligible	for	surgery,	systemic	therapy	is	usu‐
ally	recommended.	The	current	guidelines	of	the	European	Society	
of	 Medical	 Oncology	 and	 the	 National	 Comprehensive	 Cancer	
Network	recommend	the	use	of	cisplatin	and	gemcitabine	alone	or	in	
combination.7,80	In	the	absence	of	distant	metastatic	disease,	several	
locoregional	treatment	options	can	be	considered.
Hepatic	arterial	infusion	pump	(HAIP)	chemotherapy,	has	several	
theoretical	advantages	in	pCCA:	the	tumour	is	small	and	the	arterial	
supply	 is	the	prominent	component.	Since	HAIP	 is	expected	to	 in‐
crease	the	local	concentration	of	drugs,	also	the	effectiveness	is	ex‐
pected	to	be	superior	in	comparison	to	systemic	therapy.	HAIP	was	
found	to	be	more	effective	in	unresectable	iCCA	(section	below)	in	
comparison	with	other	arterial‐directed	therapies.81	However,	 lim‐
ited	data	are	available	for	pCCA.	Wang	et	al	reported	a	phase	II	study	
on	37	patients	that	were	treated	with	HAIP	with	oxaliplatin	(40	mg/
m2	for	2	hours)	plus	5‐fluorouracil	(800	mg/m2	for	22	hours	on	days	
1‐3)	every	3‐4	weeks	for	six	courses	followed	by	oral	capecitabine	
until	progression.82	They	 reported	prolonged	survival	 in	 those	pa‐
tients	 with	 periductal	 infiltrating	 pCCA	 rather	 than	 in	 those	 with	
mass‐forming	 pCCA.	 The	 overall	 toxicity	 was	 mild.	 In	 this	 study,	
there	was	no	a	control	group,	thus	limiting	the	generalizability	of	the	
conclusions.
Irreversible	electroporation	 (IRE)	 is	 a	promising	 image‐guided	
ablation	 technique	 based	 on	 short‐pulsed	 high‐voltage	 current	
fields	that	destroy	the	cell	membrane,	then	altering	the	intracellu‐
lar	compartment	leading	finally	to	cell	apoptosis.83	The	non‐ther‐
mal	physical	mechanism	implies	the	absence	of	the	heat/cold‐sink	
effect	and	of	the	damage	to	adjacent	structures	(ie,	portal	vein	and	
hepatic	artery).	This	is	the	main	advantage	of	IRE	over	other	abla‐
tive	procedures,	such	as	microwave	and	radiofrequency	ablations.	
IRE	should	be	limited	to	those	pCCA	patients	that	are	ineligible	to	
curative	 surgery.	 IRE	 aims	 to	 avoid	 or	 delay	 local	 progression	 of	
disease	with	progressive	 isolation	of	 sectoral	 and	 segmental	 bile	
ducts.	Martin	 et	 al	 showed	 the	 results	of	 a	 single‐centre	experi‐
ence	on	the	local	control	of	the	biliary	obstructions	in	26	patients	
with	unresectable	pCCA.84	They	 reported	 that	 IRE	achieved	bili‐
ary	decompression	with	a	decreased	median	time	to	biliary	drain	
removal	and	an	extended	median	time	of	biliary	drain	absence	in	
comparison	to	a	control	group.	Coelen	et	al	published	the	protocol	
of	 an	 ongoing	multicentre	 phase	 I/II	 trial	 of	 IRE	 in	 unresectable	
pCCA	patients.85
Photodynamic	therapy	(PDT)	is	another	ablative	method	used	in	
patients	with	unresectable	pCCA.	After	administration	of	a	photo‐
sensitizer	with	selective	uptake	by	cancer	cells,	PDT	activates	the	
photo‐sensitizer.	 This	 results	 in	 the	 generation	of	 oxygen	 radicals	
that	 lead	 to	 cancer	 cell	 death.	 Typically,	 5‐aminolevulinic	 acid	 is	
used	as	photo‐sensitizing,	and	the	percutaneous	route	is	preferred	
over	 the	 endoscopic	 route	 because	 of	 lower	 risks,	 increased	 fea‐
sibility,	and	easy	repeatability.86	Some	authors	reported	promising	
results	of	PDT	for	bile	duct	tumours,	with	respect	to	relief	of	jaun‐
dice,	 improvement	 in	 quality	 of	 life	 and	 improved	 survival.87‐89	 A	
main	drawback	of	PDT	is	the	photosensitization	of	the	skin,	which	
lasts	up	to	8	weeks	and	exposes	the	patient	to	skin	infections	and	
complications.
2.10 | Future research
Future	research	should	aim	to	 increase	the	R0	resection	rate.	This	
can	 be	 achieved	 by	 more	 extensive	 resection,	 particularly	 of	 the	
proximal	 bile	 ducts.	 The	 best	 option	 to	 achieve	 that	 aim	 is	 liver	
transplantation.	To	evaluate	LT	 for	pCCA,	a	prospective	study	has	
just	been	initiated	in	Germany	(pro‐duct002	trial,	DRKS00013276).	
Downstaging	with	preoperative	CRT	may	also	increase	the	R0	resec‐
tion	rate.	In	this	respect,	the	results	of	standard	chemotherapy	have	
not	been	really	promising,	but	a	combination	of	targeted	therapies	
with	 local	 irradiation	 treatment	 might	 offer	 potential	 –	 once	 ap‐
propriate	targets	for	targeted	therapies	for	this	tumour	have	been	
identified.
Another	option	 to	prevent	 recurrence	after	 resection	could	be	
adjuvant	 treatment.	 So	 far,	 adjuvant	 chemotherapy	 appears	 to	 be	
of	 limited	 value.	 New	 targeted	 therapies	 or	 immunotherapies	 are	
needed.
Finally,	reducing	perioperative	morbidity	and	mortality	is	an	im‐
portant	goal	to	improve	outcome	of	surgery.	To	achieve	that,	pCCA	
patients	should	be	treated	only	in	experienced	centres	after	referral	
prior	to	drainage.
3  | INTR AHEPATIC 
CHOL ANGIOC ARCINOMA
3.1 | Diagnostic work‐up
Intrahepatic	 cholangiocarcinoma	 (iCCA)	 arises	 in	 the	 biliary	 tree,	
proximal	to	the	second‐order	bile	ducts.	Most	iCCA	patients	are	di‐
agnosed	with	a	large	mass	on	imaging	after	presenting	with	unspe‐
cific	 complaints	 including	abdominal	pain,	weight	 loss	and	 fatigue.	
About	15%	of	patients	present	with	jaundice	caused	by	biliary	ob‐
struction.	Imaging	in	iCCA	patients	presenting	with	jaundice	shows	
a	large	mass	(ie,	>3	cm)	that	has	grown	towards	the	liver	hilum.	This	
should	be	distinguished	from	pCCA	patients	showing	a	smaller	mass	
arising	 from	 the	 biliary	 confluence	 or	 main	 hepatic	 ducts.	 iCCA	
can	also	be	diagnosed	in	an	asymptomatic	patient	who	underwent	
imaging	for	elevated	 liver	enzymes	or	a	reason	unrelated	to	 iCCA.	
The	 majority	 of	 iCCA	 patients	 have	 no	 underlying	 liver	 disease.	
Underlying	liver	disease,	however,	is	a	risk	factor	for	iCCA.	Patients	
with	cirrhosis	in	a	screening	programme	for	early	detection	of	HCC	
are	 sometimes	 found	 to	have	 iCCA.	Especially	 small	 iCCA	may	be	
difficult	 to	distinguish	 from	HCC	on	 imaging.	Sometimes,	 the	 final	
diagnosis	is	only	made	at	pathological	examination	after	surgical	re‐
section	or	liver	transplantation.
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Serum	tumour	markers	play	a	modest	role	in	the	diagnostic	work‐
up.	CA19‐9	is	elevated	in	most	patients	with	iCCA.	About	10%	of	pa‐
tients	cannot	synthesize	CA	19‐9,	and	CA	19‐9	elevation	can	also	be	
attributed	to	biliary	obstruction.	Elevated	alpha‐foetoprotein	(AFP)	
is	more	 likely	 in	patients	with	HCC.	Serum	IgG4	 is	elevated	 in	pa‐
tients	with	auto‐immune	cholangitis,	which	may	sometimes	present	
as	 an	 intrahepatic	mass.90	However,	not	 all	 patients	with	elevated	
IgG4	 have	 auto‐immune	 cholangitis	 and	 patients	 with	 elevated	
IgG4	may	also	have	cancer.	Sensitivity	and	specificity	are	improved	
when	measuring	the	IgG4/IgG	RNA	ratio.91	Many	of	these	patients	
had	long‐term	exposure	to	solvents,	oil	products	and	other	organic	
agents.	A	biopsy	or	a	course	of	steroids	should	be	considered	in	these	
patients.	Some	patients	have	a	patient	history	or	imaging	consistent	
with	another	autoimmune	disease	such	as	autoimmune	pancreatitis.
A	high	quality	tri‐phasic	CT	is	the	standard	imaging	for	iCCA	for	
both	diagnosis	and	surgical	planning.	iCCA	typically	shows	early	ar‐
terial	peripheral	enhancement	with	gradual	filling	towards	the	cen‐
tre	of	the	lesion.	Sometimes	multiple	lesions	are	present	across	the	
liver	 or	 small	 satellites	 surrounding	 a	 large	 tumour.	 An	 additional	
delayed	phase	CT	shows	progressive	enhancement	of	iCCA	lesions	
compared	to	the	surrounding	normal	liver	tissue.	A	CT	of	the	chest	is	
recommended	to	rule	out	pulmonary	metastases.	In	most	patients,	
a	CT	is	sufficient	for	diagnosis	and	treatment	plan.	MRI	can	be	per‐
formed	instead	of	or	in	addition	to	CT,	when	the	diagnosis	is	uncer‐
tain.	A	recent	study	compared	contrast‐enhanced	MRI	for	HCC	and	
iCCA.	None	of	the	imaging	features	was	unique	to	iCCA.	However,	
HCC	was	more	 likely	to	show	wash‐out,	capsule	and	 intra‐lesional	
fat;	iCCA	was	more	likely	to	show	peripheral	arterial	phase	enhance‐
ment	 and	 progressive	 central	 enhancement.92	Moreover,	MRCP	 is	
superior	in	delineation	of	the	biliary	extent	of	tumours	growing	to‐
wards	the	 liver	hilum	and	causing	biliary	obstruction.	PET‐CT	may	
find	 lesions	 suspicious	 for	metastastic	 disease	 that	were	 not	 visi‐
ble	on	CT.	Unfortunately,	PET‐CT	has	a	low	yield	of	about	10%	for	
finding	occult	metastases	and	a	considerable	risk	of	false‐negative	
findings	 requiring	additional	 invasive	diagnostic	 tests	and	delay	of	
surgery.9,10	We	recommend	FDG‐PET	only	in	patients	with	very	ex‐
tensive	disease	(eg,	multiple	lesions)	or	a	high	surgical	risk.
A	percutaneous	biopsy	for	suspected	iCCA	is	rarely	indicated	if	
a	patient	is	eligible	for	complete	resection.	Moreover,	it	is	typically	
avoided	because	of	 the	 risk	of	 recurrent	disease	 along	 the	biopsy	
tract.	Imaging	mostly	provides	a	high	degree	of	certainty	about	the	
diagnosis.	If	imaging	is	not	specific	for	iCCA	and	CA	19‐9	is	normal,	
one	should	rule	out	that	the	liver	tumour(s)	represent	metastatic	dis‐
ease	of	another	malignancy,	in	particular	colorectal,	gastric	or	breast	
cancer.	Work‐up	should	 then	 include	a	colonoscopy,	upper	endos‐
copy	and	mammography.	Pathological	evaluation	including	immuno‐
histochemistry	may	not	be	able	to	distinguish	iCCA	from	metastatic	
disease.
3.2 | Indication for resection
The	decision	for	surgical	resection	of	iCCA	requires	a	trade‐off	be‐
tween	 anticipated	oncological	 benefit	 (ie,	 superior	OS	 and	quality	
of	 life)	vs	surgical	 risk	 (ie,	post‐operative	mortality	and	morbidity).	
This	trade‐off	is	easy	in	a	healthy	young	patient	with	a	solitary	3	cm	
lesion	in	segment	3	of	the	liver.	At	the	other	end	of	the	spectrum	is	
a	frail	octogenerian	with	a	10‐cm	lesion	with	several	satellites	and	
suspicious	hilar	lymph	nodes	who	requires	an	extended	right	hemi‐
hepatectomy.	Shared	decision	making	 requires	 the	combination	of	
patient	preference	with	oncological	benefit	and	surgical	risk.
Resection	in	the	setting	of	distant	(extrahepatic)	metastatic	dis‐
ease	results	in	median	OS	similar	to	palliative	chemotherapy.	Patients	
with	nodal	involvement	beyond	the	hepatoduodenal	and	gastrohe‐
patic	ligament	are	also	less	likely	to	benefit	from	a	resection.	Even	
patients	with	locoregional	nodal	metastases	have	a	recurrence	rate	
approaching	100%.93	Nevertheless,	most	iCCA	patients	will	die	from	
liver	disease.	Therefore,	controlling	disease	in	the	liver	with	surgery	
can	improve	survival,	even	when	cure	is	not	likely.	A	SEER	database	
study	of	169	node‐positive	iCCA	patients,	however,	found	a	median	
OS	of	only	19	months	after	resection,	vs	20	months	with	systemic	
chemotherapy	alone	(P = 0.32).94	iCCA	patients	with	more	than	one	
lesion	also	have	a	worse	OS	and	are	 less	 likely	to	benefit	 from	re‐
section.	Several	 studies	 found	a	5‐year	OS	of	 about	10%	with	 re‐
section	 in	 patients	with	multiple	 tumours.95,96	 Resection	 could	 be	
considered	 in	 selected	 iCCA	patients	with	 two	 to	 three	 lesions.	A	
large	multicentre	study	reported	similar	OS	for	patients	who	did	and	
did	not	undergo	vascular	reconstruction	of	the	hepatic	artery,	portal	
vein,	vena	cava	or	hepatic	veins.97
3.3 | Approaches to resection
The	aim	of	resection	for	iCCA	is	similar	to	any	oncological	liver	resec‐
tion:	a	complete	(R0)	resection	with	an	adequate	liver	remnant.	Most	
patients	have	a	single	large	tumour	requiring	an	(extended)	hemihe‐
patectomy.	PVE	is	recommended	if	the	future	liver	remnant	volume	
is	below	30%‐40%	(see	section	on	PVE	in	first	part	on	pCCA).	ALPPS	
can	be	considered	if	the	remnant	volume	remains	inadequate	after	
PVE	or	 if	 intraoperatively	a	 larger	 resection	 is	needed	than	antici‐
pated	on	imaging.98
About	15%	of	iCCA	patients	who	undergo	a	resection	presented	
with	biliary	obstruction.	Most	of	these	patients	will	require	preop‐
erative	biliary	drainage,	in	particular	in	the	setting	of	cholangitis	or	a	
small	FLR	(see	also	section	on	biliary	drainage	in	first	part	on	pCCA).	
Resection	without	biliary	drainage	should	be	considered	 if	 the	 fu‐
ture	liver	remnant	exceeds	50%.	Resection	of	the	biliary	confluens	
is	typically	needed	in	patients	with	biliary	obstruction,	followed	by	a	
roux‐Y	hepaticojejunostomy.
Staging	 laparoscopy	 should	 be	 considered	 in	 all	 patients	 with	
iCCA	 to	 rule	 out	 occult	 metastastic	 disease.	 This	 risk	 is	 particu‐
larly	 high	 in	 patients	 with	 high	 CA	 19‐9,	 major	 vascular	 invasion	
and	 suspicious	 lymph	 nodes.99	 Exploratory	 laparotomy	 without	
resection	 should	 be	 avoided	 because	 it	 delays	 palliative	 systemic	
chemotherapy.
Suspicious	 lymph	 nodes	 beyond	 the	 hepatoduodenal	 ligament	
should	be	sent	for	frozen	section.	However,	preoperative	assessment	
of	suspicious	aortocaval	and	truncal	 lymph	nodes	with	endoscopic	
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ultrasound	and	 fine	needle	aspiration	 is	preferred.	Guidelines	 rec‐
ommend	to	perform	a	lymphadenectomy	in	all	patients	with	resect‐
able	iCCA.99	For	optimal	staging,	the	8th	edition	of	the	AJCC	staging	
systems	 recommends	 to	 harvest	 at	 least	 six	 locoregional	 lymph	
nodes.1	It	appears	that	lymphadenectomy	is	mainly	a	staging	proce‐
dure	with	little	effect	on	OS.
3.4 | Perioperative systemic chemotherapy
Systemic	chemotherapy	with	gemcitabine	and	cisplatin	is	the	stand‐
ard	of	care	in	patients	with	advanced	biliary	cancer.100	The	ABC‐02	
RCT	found	a	superior	median	OS	of	11.7	months	with	gemcitabine	
and	cisplatin,	compared	to	8.2	months	with	gemcitabine	alone.	The	
hazard	ratio	(HR)	for	the	subgroup	of	80	patients	with	iCCA	was	0.57	
(95%	CI:	0.34‐0.94).
Several	RCTs	 investigated	 systemic	 chemotherapy	 in	 the	 adju‐
vant	setting.	The	BILCAP	trial	compared	adjuvant	capecitabine	with	
observation.	The	study	included	447	patients	with	biliary	cancer,	of	
whom	84	had	 iCCA.	The	median	OS	was	51	months	with	capecit‐
abine	vs	36	months	with	observation	 (HR	0.80;	95%	CI	0.63‐1.04:	
P	=	0.097).101	 The	 BCAT	 trial	 found	 no	 survival	 difference	 be‐
tween	 gemcitabine	with	 observation	 (HR	 1.01;	 95%	CI	 0.70‐1.45;	
P	=	0.97).102	 However,	 the	 BCAT	 trial	 only	 included	 patients	 with	
extrahepatic	cholangiocarcinoma.	Finally,	the	Prodige‐11	trial	com‐
pared	adjuvant	gemcitabine	plus	oxaliplatin	vs	observation	after	re‐
section	of	biliary	cancer	and	also	found	no	survival	benefit	(HR	1.08;	
95%	CI	0.70‐1.66).103	These	three	trials	have	insufficient	power	for	
a	definitive	recommendation	of	adjuvant	chemotherapy.	Meanwhile,	
the	ACTICCA	−1	trial	(sample	size	781)	is	still	recruiting	patients	to	
compare	adjuvant	gemcitabine	with	cisplatin	vs	capecitabine	alone	
(NCT02170090).
Preoperative	 systemic	 chemotherapy	 for	 patients	with	 resect‐
able	or	unresectable	iCCA	has	not	been	evaluated	in	an	RCT.	A	multi‐
national	study	included	62	patients	with	resectable	or	unresectable	
iCCA	who	 received	 preoperative	 systemic	 chemotherapy.104	 They	
found	 a	 median	 OS	 of	 47	months	 for	 patients	 who	 underwent	 a	
complete	 resection	 after	 preoperative	 chemotherapy.	 In	 a	 recent	
study	of	74	patients	with	unresectable	iCCA,	39	patients	(53%)	un‐
derwent	a	resection	after	a	median	of	six	cycles	of	systemic	chemo‐
therapy.	 The	median	OS	was	 24	months	 after	 completion	 of	 both	
induction	 chemotherapy	 and	 surgical	 resection,	which	was	 similar	
to	a	separate	cohort	of	patients	who	underwent	upfront	surgery	for	
resectable	iCCA	with	a	median	OS	of	26	months.105	This	outcome	is	
superior	to	OS	with	palliative	systemic	chemotherapy	without	resec‐
tion	in	the	ABC‐02	trial.100	Preoperative	systemic	chemotherapy	can	
be	considered	as	a	 “test	of	 time”.	Downstaging	 from	unresectable	
to	resectable	with	systemic	chemotherapy	may	be	succesful	in	rare	
cases.
3.5 | Outcomes after resection
Post‐operative	mortality	after	resection	for	iCCA	depends	on	both	
patient	and	tumour	characteristics.	A	minor	liver	resection1‐3	should	
have	 a	 mortality	 rate	 of	 about	 1%	 in	 high‐volume	 centres.	 Most	
patients	with	 iCCA	 (75%)	will	 require	 an	 (extended)	 hemihepatec‐
tomy	 with	 higher	 mortality.106	 Post‐operative	 mortality	 is	 further	
increased	in	patients	requiring	vascular	(portal	vein,	hepatic	artery	
or	caval	vein)	 reconstructions,	patients	with	cirrhosis	and	patients	
requiring	preoperative	biliary	drainage.
Most	 patients	 will	 develop	 recurrent	 disease	 after	 resection	 of	
iCCA.	The	median	recurrence‐free	survival	in	a	large	study	of	301	pa‐
tients	was	20	months.	Most	patients	developed	an	initial	intrahepatic	
recurrence	(61%).	An	initial	extrahepatic	recurrence	was	found	in	21%	
and	19%	had	 a	 simultaneous	 intra‐	 and	 extrahepatic	 recurrence.	 107 
Another	study	of	189	patients	found	that	the	initial	recurrence	within	
24	months	was	only	intrahepatic	in	54%	of	patients	with	a	recurrence,	
compared	to	33%	after	24	months.93	Small	studies	have	reported	fa‐
vourable	outcomes	after	resection	of	recurrence	in	selected	patients.108
The	median	OS	after	curative‐intent	resection	is	about	30	months	
with	a	5‐year	OS	of	about	30%	based	on	several	large	series.109	Most	
patients	died	from	recurrent	disease.	Poor	prognostic	factors	for	OS	
include	the	presence	of	multiple	tumours,	large	tumour	size,	vascular	
invasion,	lymph	node	involvement,	poor	tumour	differentiation	and	
a	positive	surgical	resection	margin.	Several	prognostic	models	were	
developed	for	survival	after	resection	of	iCCA.	Most	models	used	a	
combination	of	known	poor	prognostic	factors.	The	model	of	Wang	
et	al	also	included	serum	tumour	markers	(CA	19‐9	and	CEA)	and	had	
the	best	c‐statistic	of	0.74.110
3.6 | Liver transplantation
Historical	 series	 of	 liver	 transplantation	 for	 unresectable	 iCCA	
showed	a	poor	5‐year	OS	below	25%.111	Considering	these	poor	out‐
comes	and	the	scarcity	of	organs,	iCCA	has	been	a	contraindication	
for	liver	transplantation.	A	recent	series	found	that	cirrhotic	patients	
with	uninodular	iCCA	of	less	than	2	cm	had	a	similar	OS	after	liver	
transplantation	as	matched	HCC	patients.112	More	recently,	highly	
selected	patients	with	well‐differentiated	iCCA	of	less	than	2	cm	(ie,	
very	early	iCCA)	had	a	5‐year	OS	of	65%.113	However,	both	studies	
apply	only	to	a	small	proportion	of	patients	with	iCCA.
Liver	transplantation	has	also	been	performed	for	unresectable	
iCCA	 in	 12	 patients	with	 stable	 disease	 on	 neoadjuvant	 systemic	
chemotherapy.46	Three	patients	(25%)	developed	recurrent	disease	
within	one	year.	Living	donor	liver	transplantation	may	expand	the	
role	of	transplantation	for	iCCA.	Careful	patient	selection	is	needed	
of	patients	who	are	not	expected	 to	develop	extrahepatic	disease	
within	a	few	years	after	transplantation.
3.7 | Locoregional treatments
Surgical	 resection	 is	 the	preferred	 treatment	 for	 resectable	 iCCA.	
However,	a	lesion	of	less	than	2	or	3	cm	located	centrally	in	the	liver	
could	be	considered	for	 thermal	ablation	 (eg,	RFA	or	MWA)	 in	pa‐
tients	with	a	high	surgical	risk	(eg,	cirrhosis).	The	main	drawback	of	
thermal	ablation	 is	an	 increased	 risk	of	 local	 recurrence.	Omission	
of	lymphadenectomy	is	less	concerning:	nodal	metastasis	is	unlikely	
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in	 small	 lesions,	 and	 removing	positive	 lymph	nodes	has	not	been	
shown	to	improve	survival.
Locoregional	 treatments	 are	 mainly	 applied	 in	 patients	 with	
unresectable	 disease.	 The	median	OS	with	 systemic	 chemother‐
apy	 (gemcitabine	 with	 cisplatin)	 for	 patients	 with	 unresectable	
iCCA	 is	 <1	year	 with	 very	 few	 survivors	 beyond	 2	years.100,114 
Most	patients	with	iCCA	eventually	die	from	tumour	burden	lim‐
ited	to	the	liver.	Progressive	disease	in	the	liver	eventually	causes	
biliary	obstruction	and	 liver	 failure.	Locoregional	 treatments	aim	
to	 improve	 survival	 by	 controlling	disease	 in	 the	 liver	 as	 long	 as	
possible.	If	local	control	is	succesful,	most	patients	will	eventually	
die	from	distant	metastases.
Unresectable	 iCCA	 is	 too	 large	 for	 percutaneous	 ablation.	
Therefore,	various	transarterial	treatments	have	been	investigated.	
Transarterial	chemo‐embolization	(TACE)	causes	ischaemia	and	de‐
livers	cytotoxic	agents.	Two	small	studies	reported	a	median	OS	of	12	
and	18	months.115,116	Radioembolization	with	90Y	has	shown	prom‐
ising	results	in	patients	with	unresectable	HCC	and	colorectal	liver	
metastases.	 Hepatic	 arterial	 infusion	 pump	 (HAIP)	 chemotherapy	
with	floxuridine	has	been	investigated	in	a	study	of	104	patients.117 
Because	 floxuridine,	which	 is	 similar	 to	5‐FU,	has	a	95%	first‐pass	
effect,	it	can	be	delivered	in	the	hepatic	artery	at	a	very	high	dose.	
The	partial	response	rate	was	about	60%.	Median	OS	was	31	months	
compared	to	18	months	in	patients	who	received	systemic	chemo‐
therapy	alone.	Five‐year	OS	was	20%	in	patients	who	received	HAIP	
chemotherapy.	Although	no	direct	comparison	has	been	performed,	
the	results	of	HAIP	chemotherapy	are	promising.
3.8 | Future research
Future	research	should	improve	patient	selection	for	resection	of	iCCA.	
Resection	is	technically	feasible	even	in	patients	with	multiple	lesions	or	
requiring	vascular	reconstruction.	However,	a	small	survival	benefit	may	
not	justify	considerable	post‐operative	mortality,	particularly	in	frail	pa‐
tients.	Predictive	models	for	survival	with	and	without	resection	vs	the	
risk	of	post‐operative	complications	could	aid	shared	decision‐making.
Most	patients	will	develop	recurrent	disease	after	resection	of	
iCCA.	Several	RCTs	 investigating	adjuvant	systemic	chemotherapy	
for	 biliary	 cancer	 found	 conflicting	 results.	 Better	 adjuvant	 treat‐
ments	 are	needed	 to	 address	occult	metastatic	 disease.	 Induction	
HAIP	chemotherapy	demonstrated	a	high	response	rate	in	unresect‐
able	 iCCA	and	could	also	reduce	the	high	 intra‐hepatic	recurrence	
rate	in	the	adjuvant	setting.	Personalized	systemic	treatments	in	the	
preoperative	 and	 adjuvant	 setting	based	on	molecular	 profiling	of	
tumours	may	further	improve	outcomes.
Finally,	 a	 minimal‐invasive	 (laparoscopic	 or	 robotic)	 approach	
may	have	a	modest	impact	on	post‐operative	complications	and	re‐
covery,	but	probably	not	on	survival	outcomes.
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